Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

A new oral drug caused dramatic shrinkage of a patient's rare, aggressive form of soft-tissue cancer that was driven by an abnormally activated protein, physician-scientists from Dana-Farber Cancer Institute report in the Oct. 28 issue of the New England Journal of Medicine.

28 Oct 2010

Sandoz initiates voluntary recall of Methotrexate Injection

Sandoz Inc. announced today it has initiated a voluntary recall in the US of all 50mg/2mL and 250mg/10mL vials of Sandoz and Parenta brand Methotrexate Injection, USP product ("methotrexate") to the consumer/user level. Consistent with its commitment to quality and patient safety, Sandoz is initiating this voluntary recall of all 24 lots of the affected product following the finding of small glass flakes by Sandoz quality control in a limited number of vials in four lots.

28 Oct 2010

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Biogen Idec Inc. a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its third quarter 2010 results.

26 Oct 2010

Study finds ABVD standard chemotherapy effective for Hodgkin's lymphoma

A lower dose of radiation used to reduce side effects is not as effective as the regular dose when given with the standard chemotherapy in the treatment of Hodgkin's lymphoma patients with early, intermediate-stage disease, according to a first-of-its-kind randomized study presented at the plenary session, November 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

26 Oct 2010

Viral microRNA allows EBV to hide within cells and evade immune system

While most commonly associated with mononucleosis, Epstein-Barr virus (EBV) has been linked to many diseases that affect people long after the initial infection takes place, including some forms of cancer. In the current issue of the Journal of Biological Chemistry, scientists at The Wistar Institute describe how viral microRNA - small segments of RNA that suppress the effects of gene activity - allows EBV to hide within cells and evade the immune system.

26 Oct 2010

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the presentation of Phase II data from Hodgkin Lymphoma patients treated in the 1st Simon Stage cohort of the ongoing SAPHIRE study with resminostat (4SC-201), an oral pan-histone deacetylase (HDAC) inhibitor, at the 8th International Symposium on Hodgkin Lymphoma in Cologne, Germany.

26 Oct 2010

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

Genmab A/S announced today the start of a Phase III study of single agent ofatumumab compared to single agent rituximab in patients with follicular non-Hodgkin's lymphoma (NHL) that has relapsed at least 6 months after completion of treatment with a rituximab-containing regimen to which they responded.

26 Oct 2010

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

The John Theurer Cancer Center at Hackensack University Medical Center unveiled a new $130-million, 155,000-square-foot comprehensive cancer facility that will enhance the cancer center's ability to deliver multidisciplinary extraordinary care, best-in-class clinical quality, and cutting-edge research. The doors will open for patients in January 2011.

26 Oct 2010

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that brentuximab vedotin (SGN-35) will be featured in three poster presentations at the 8th International Symposium on Hodgkin Lymphoma (ISHL) being held October 23-26, 2010 in Cologne, Germany.

25 Oct 2010

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

Antigenics, Inc. today announced the expansion of a phase 2 clinical study of HSPPC-96 (Oncophage® vaccine; vitespen), Antigenics' personalized therapeutic cancer vaccine, in patients with newly diagnosed glioma.

25 Oct 2010

BAFF protein can promote aggressive leukemia and lymphomas

Chronic lymphocytic leukemia (CLL) cells survive and thrive not just by their own innate wiles, but by also acquiring aid and support from host cells in their surrounding environment.

25 Oct 2010

GE Healthcare signs definitive agreement to acquire Clarient

GE Healthcare, a unit of General Electric Company and Clarient, Inc. announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the fast-growing molecular diagnostics sector.

25 Oct 2010

Biogen, Genentech announce new structure of anti-CD20 collaboration

Biogen Idec and Genentech, Inc. a wholly owned member of the Roche Group today announced that they have agreed to amend their collaboration on antibodies targeting CD20.

22 Oct 2010

LSUHSC receives NIH grant for research on cancer and infectious diseases

LSU Health Sciences Center New Orleans has been awarded $12 million over five years by the National Institutes of Health to conduct research on diseases like prostate and stomach cancers, lymphoma and leukemia, dengue fever, tuberculosis, and herpes infections, as well as to support the development of academic research scientists.

21 Oct 2010

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of castration-resistant prostate cancer. ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen and is being co-developed by both companies for the treatment of solid tumors.

21 Oct 2010

Genoptix ranked #41 on Deloitte's Technology Fast 500

Genoptix, Inc., a specialized laboratory services provider, today announced that it ranked number 41 on Technology Fast 500™, Deloitte's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the five year period from 2005–2009. Genoptix grew 3,451 percent during this period.

20 Oct 2010

SHIP and PTEN enzymes act cooperatively to suppress B cell lymphoma: Study

Lymphoma is a cancer of the immune system. White blood cells divide again and again, spreading abnormally throughout the body. Lymphomas can arise from two types of white blood cells, T cells or B cells, which divide uncontrollably when the molecular mechanisms that keep them in check go awry.

20 Oct 2010

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

The US Department of Defense (DOD) has awarded a $5 million grant to The Feinstein Institute for Medical Research and the University of Cincinnati to further develop a "lab-on-a-chip" device used for monitoring patients suffering from severe brain injury.

19 Oct 2010

EMA Pediatric Committee adopts positive opinion for CTI's Pixuvri for lymphoid malignancies, solid tumors

Cell Therapeutics, Inc. ("CTI") announced today that the Pediatric Committee (the "PDCO") of the European Medicines Agency ("EMA") has adopted an opinion agreeing to CTI's Pixuvri® (pixantrone dimaleate) Pediatric Investigation Plan ("PIP") for the treatment of lymphoid malignancies and solid tumors in children between ages of 6 months and 18 years.

19 Oct 2010

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Findings from the PRECiSE 3 (P3) open label extension study for Cimzia, demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20. Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

19 Oct 2010

Lymphoma News and Research

Further Reading

New oral drug shrinks IMT sarcoma driven by abnormally activated protein

Sandoz initiates voluntary recall of Methotrexate Injection

Biogen 2010 third quarter revenue increase 5% to $1.2 billion

Study finds ABVD standard chemotherapy effective for Hodgkin's lymphoma

Viral microRNA allows EBV to hide within cells and evade immune system

Phase II data from resminostat SAPHIRE study to be presented at International Hodgkin Lymphoma Symposium

Genmab begins Phase III head to head study of ofatumumab vs. rituximab in follicular NHL

John Theurer Cancer Center unveils new $130M, 155,000-square-foot comprehensive facility

Seattle Genetics, Millennium to feature SGN-35 in three poster presentations at ISHL symposium

Antigenics expands HSPPC-96 Phase 2 clinical study in glioma

BAFF protein can promote aggressive leukemia and lymphomas

GE Healthcare signs definitive agreement to acquire Clarient

Biogen, Genentech announce new structure of anti-CD20 collaboration

LSUHSC receives NIH grant for research on cancer and infectious diseases

Agensys and Seattle Genetics initiate ASG-5ME phase I clinical trial for castration-resistant prostate cancer

Genoptix ranked #41 on Deloitte's Technology Fast 500

SHIP and PTEN enzymes act cooperatively to suppress B cell lymphoma: Study

DOD awards grant to develop ‘lab-on-a-chip’ device for monitoring patients with severe brain injury

EMA Pediatric Committee adopts positive opinion for CTI's Pixuvri for lymphoid malignancies, solid tumors

UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific Meeting

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News